-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cancer is a major problem that threatens human health.
Recently, anti-cancer drugs that can clear cancer cells by 1.
2 million injections and the Internet have become the focus of attention of netizens and patients
.
What is sacred of this medicine? It is understood that the drug is called Akirensai injection (trade name: Yikaida), which is an immunotherapy drug, which belongs to CAR-T therapy and is mainly used to treat lymphoma
.
According to media reports, after two months of treatment with this drug, Ms.
Chen in Shanghai found that there were no cancer cells in the body temporarily and the symptoms were completely relieved
.
As soon as the news came out, the majority of patients thought that they had found hope in fighting cancer, but they were also embarrassed at the price of up to one house
.
So, why is this anti-cancer drug so expensive? According to industry insiders, in the field of tumor immunotherapy, CAR-T cell therapy is a very breakthrough therapy
.
This therapy is a "tailor-made" therapy.
The entire implementation process is relatively complicated and requires high costs, including research and development costs, production costs, etc.
, which are huge expenses
.
According to the president of Fosun Kate, the manufacturer of the drug, domestic CAR-T cell therapy drugs are produced by the company based on the technology introduced by the United States kite company.
The current overseas listed CAR-T drugs are priced at US$373,000 to US$430,000.
, Equivalent to RMB 2.
4 million-3 million
.
It can be seen that relative to foreign countries, the price of this domestic CAR-T therapy is already very conscientious
.
According to his description, this CAR-T drug is different from traditional drugs.
It is a personal customized living cell drug.
The research and development, quality management and production costs are very high.
On the one hand, domestic pricing is based on the overall international price, and the company makes part of it.
Let profit; on the other hand, considering that CAR-T treatment requires high technical personnel and involves complicated processes, it is not an easy task to reduce costs with the existing process and quality control standards
.
It is worth mentioning that for ordinary patients, 1.
2 million injections are still an unaffordable cost.
So, is there any hope of reducing the price of domestic CAR-T therapy? When will the price be reduced? In fact, while the majority of patients are looking forward to lowering prices, commercial insurance companies have already begun to take action.
It is reported that some health insurance products of Ping An Life, Ping An Health, Fosun United Health, and ZhongAn Insurance include Akilunza injection in the insurance coverage.
.
Fosun Kate stated that it will continue to invest and actively cooperate with multiple parties to reduce the payment pressure and benefit patients as much as possible through patient assistance programs, innovative payment models and commercial insurance
.
In addition, judging from the new version of the National Medical Insurance Catalogue officially launched on March 1 this year, 17 anti-cancer drugs including lenvatinib, trametinib, dabrafenib, etc.
, have all entered the medical insurance catalog The price is reduced significantly, and the reimbursement rate is as high as 70%
.
On July 30, the National Medical Insurance Administration announced the "List of Drugs Approved for the 2021 National Medical Insurance Drug Catalog Adjustment Passed the Preliminary Formal Examination", including Akirensai injection
.
In this regard, the industry believes that the possibility of CAR-T therapy entering medical insurance in the future is not ruled out
.
However, “only means that the drug meets the application requirements after preliminary review, and has obtained the qualification to enter the next adjustment link
.
Whether such drugs can eventually enter the national medical insurance drug list, but also subject to strict evaluation including economics, exclusive drugs Only after price negotiation can the successful negotiation enter the catalog"
.
Recently, anti-cancer drugs that can clear cancer cells by 1.
2 million injections and the Internet have become the focus of attention of netizens and patients
.
What is sacred of this medicine? It is understood that the drug is called Akirensai injection (trade name: Yikaida), which is an immunotherapy drug, which belongs to CAR-T therapy and is mainly used to treat lymphoma
.
According to media reports, after two months of treatment with this drug, Ms.
Chen in Shanghai found that there were no cancer cells in the body temporarily and the symptoms were completely relieved
.
As soon as the news came out, the majority of patients thought that they had found hope in fighting cancer, but they were also embarrassed at the price of up to one house
.
So, why is this anti-cancer drug so expensive? According to industry insiders, in the field of tumor immunotherapy, CAR-T cell therapy is a very breakthrough therapy
.
This therapy is a "tailor-made" therapy.
The entire implementation process is relatively complicated and requires high costs, including research and development costs, production costs, etc.
, which are huge expenses
.
According to the president of Fosun Kate, the manufacturer of the drug, domestic CAR-T cell therapy drugs are produced by the company based on the technology introduced by the United States kite company.
The current overseas listed CAR-T drugs are priced at US$373,000 to US$430,000.
, Equivalent to RMB 2.
4 million-3 million
.
It can be seen that relative to foreign countries, the price of this domestic CAR-T therapy is already very conscientious
.
According to his description, this CAR-T drug is different from traditional drugs.
It is a personal customized living cell drug.
The research and development, quality management and production costs are very high.
On the one hand, domestic pricing is based on the overall international price, and the company makes part of it.
Let profit; on the other hand, considering that CAR-T treatment requires high technical personnel and involves complicated processes, it is not an easy task to reduce costs with the existing process and quality control standards
.
It is worth mentioning that for ordinary patients, 1.
2 million injections are still an unaffordable cost.
So, is there any hope of reducing the price of domestic CAR-T therapy? When will the price be reduced? In fact, while the majority of patients are looking forward to lowering prices, commercial insurance companies have already begun to take action.
It is reported that some health insurance products of Ping An Life, Ping An Health, Fosun United Health, and ZhongAn Insurance include Akilunza injection in the insurance coverage.
.
Fosun Kate stated that it will continue to invest and actively cooperate with multiple parties to reduce the payment pressure and benefit patients as much as possible through patient assistance programs, innovative payment models and commercial insurance
.
In addition, judging from the new version of the National Medical Insurance Catalogue officially launched on March 1 this year, 17 anti-cancer drugs including lenvatinib, trametinib, dabrafenib, etc.
, have all entered the medical insurance catalog The price is reduced significantly, and the reimbursement rate is as high as 70%
.
On July 30, the National Medical Insurance Administration announced the "List of Drugs Approved for the 2021 National Medical Insurance Drug Catalog Adjustment Passed the Preliminary Formal Examination", including Akirensai injection
.
In this regard, the industry believes that the possibility of CAR-T therapy entering medical insurance in the future is not ruled out
.
However, “only means that the drug meets the application requirements after preliminary review, and has obtained the qualification to enter the next adjustment link
.
Whether such drugs can eventually enter the national medical insurance drug list, but also subject to strict evaluation including economics, exclusive drugs Only after price negotiation can the successful negotiation enter the catalog"
.
